Promising Nonalcoholic Steatohepatitis Therapies such as AZD2693, Saroglitazar Magnesium 4 mg, Semaglutide (SEMA), Cilofexor ...

The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.

Ardelyx (ARDX) announced the approval of a New Drug Application, NDA, by China’s Center for Drug Evaluation of the National Medical Products Administration for tenapanor to control serum ...

Treatments for dry eye disease, neuroendocrine tumors, chronic spontaneous urticaria, Barth syndrome, and migraine are under review.

Antengene’s new drug application (NDA) for Xpovio (selinexor) has gained approval from the Indonesia National Agency of Drug ...

Discover how outsourcing regulatory submission content development improves efficiency and ensures compliance.

The NDA approval for tenapanor in China supports Ardelyx's goal of addressing significant unmet medical needs in patients with chronic kidney disease. The approval triggers a $5 million milestone ...

The FDA accepted a new drug application for SYD-101 to slow the progression of pediatric myopia and assigned a Prescription ...

Andhra Pradesh SIPB approves ₹3.10 lakh crore investments, targeting 3.12 lakh jobs, including major projects by ...

Aldeyra's reproxalap faced an FDA setback but showed positive trial results, leading to a resubmitted NDA. Click here to find ...

Company expects to submit New Drug Application (NDA) in April 2025 - DEER PARK, Ill., March 14, 2025 (GLOBE NEWSWIRE) -- Eton ...